Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205

Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205

Bibliographic Details
Main Authors:	Hoehler, T, von Wichert, G, Schimanski, C, Kanzler, S, Moehler, M H, Hinke, A, Seufferlein, T, Siebler, J, Hochhaus, A, Arnold, D, Hallek, M, Hofheinz, R, Hacker, U T
Format:	Online
Language:	English
Published:	Nature Publishing Group 2013
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776974/

Similar Items

Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial
by: Stein, Alexander, et al.
Published: (2013)

Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial
by: Stintzing, S, et al.
Published: (2011)

A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial
by: Giessen, Clemens, et al.
Published: (2011)

VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
by: Thomaidis, Thomas, et al.
Published: (2014)

DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma
by: Ettrich, Thomas J., et al.
Published: (2016)

Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis
by: Buchler, Tomas, et al.
Published: (2014)

Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial
by: von Einem, J. C., et al.
Published: (2014)

Phase I study of imatinib, cisplatin and 5-fluoruracil or capecitabine in advanced esophageal and gastric adenocarcinoma
by: Mayr, Martina, et al.
Published: (2012)

EHMTI-0205. Methodology guidelines for population surveys of headache prevalence, burden and cost
by: Stovner, L, et al.
Published: (2014)

Combination of Capecitabine and Oxaliplatin is an Effective Treatment Option for Advanced Neuroendocrine Tumors
by: Ferrarotto, Renata, et al.
Published: (2013)

Combination of capecitabine and oxaliplatin is an effective treatment option for advanced neuroendocrine tumors
by: Renata Ferrarotto, et al.
Published: (2013-09-01)

Economic comparison of capecitabine + oxaliplatin and 5-fluorouracil + oxaliplatin in the adjuvant treatment of colon cancer
by: Aitini, Enrico, et al.
Published: (2012)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial
by: Madi, A, et al.
Published: (2012)

A Muti-center, Randomized Phase II Study of Oxaliplatin and S-1 versus Capecitabine and Oxaliplatin in Patients with Metastatic Colorectal Cancer
by: Kim, Jung Han, et al.
Published: (2015)

A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers
by: Halperin, Daniel M, et al.
Published: (2014)

Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer
by: Dellas, Kathrin, et al.
Published: (2013)

Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab
by: Liu, Yingmiao, et al.
Published: (2013)

Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer
by: Munemoto, Yoshinori, et al.
Published: (2015)

Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer
by: Bazarbashi, Shouki, et al.
Published: (2015)

Tissue MicroRNAs as Predictors of Outcome in Patients with Metastatic Colorectal Cancer Treated with First Line Capecitabine and Oxaliplatin with or without Bevacizumab
by: Boisen, Mogens K., et al.
Published: (2014)

First-line bevacizumab and capecitabine–oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study
by: Feliu, J, et al.
Published: (2014)

Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report
by: Sprinzl, Martin F, et al.
Published: (2006)

Capecitabine-associated hand–foot–skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer
by: Hofheinz, R-D, et al.
Published: (2012)

A Phase II Study of Sequential Capecitabine Plus Oxaliplatin Followed by Docetaxel Plus Capecitabine in Patients With Unresectable Gastric Adenocarcinoma: The TCOG 3211 Clinical Trial
by: Chen, Ming-Huang, et al.
Published: (2016)

Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program
by: Moehler, Markus, et al.
Published: (2016)

Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer
by: Harder, J, et al.
Published: (2012)

P02.05. Clinical practice outcomes of an individualized integrative intervention for chronic pain: results from the BraveNet PBRN
by: Abrams, D
Published: (2012)

OA02.05. Antimicrobial activity of Rasamanikya against different pathogenic microbes w.s.r. to skin disease
by: Kumari, Poonam, et al.
Published: (2013)

PA02.05. Pharmaceutical and analytical evaluation of Lasuna Kshirpaka w.s.r to charaka and sharangadhara methods.
by: Suryawanshi, Nilesh
Published: (2013)

Genome Wide Association Study for Predictors of Progression Free Survival in Patients on Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in First-Line Therapy of Metastatic Colorectal Cancer
by: Pander, Jan, et al.
Published: (2015)

Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study
by: Jackson, Christopher GCA, et al.
Published: (2014)

A case of advanced intrahepatic cholangiocarcinoma accidentally, but successfully, treated with capecitabine plus oxaliplatin (CAPOX) therapy combined with bevacizumab: a case report
by: Uji, Masahito, et al.
Published: (2016)

Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies
by: Mammoliti, S., et al.
Published: (2011)

The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer
by: Hansen, Torben Frøstrup, et al.
Published: (2012)

Efficacy and Safety of Docetaxel Plus Oxaliplatin and Capecitabine in the First Line Treatment of Advanced Gastric Adenocarcinoma
by: Liu, Ying, et al.
Published: (2013)

Lethal cardiotoxicity, steatohepatitis, chronic pancreatitis, and acute enteritis induced by capecitabine and oxaliplatin in a 36-year-old woman
by: Gurzu, Simona, et al.
Published: (2013)

Capecitabine and Oxaliplatin (XELOX) for the Treatment of Patients with Metastatic Gastric Cancer and Severe Liver Dysfunction
by: Hwang, Seung Jae, et al.
Published: (2006)

Prospective clinical study of capecitabine plus oxaliplatin concurrent chemoradiotherapy after radical resection of rectal cancer
by: Wanghua Chen, et al.
Published: (2018-08-01)

Factors Influencing Clinicians' Choice of Adjuvant S-1 versus Capecitabine plus Oxaliplatin after Curative Gastrectomy in Patients with Gastric Cancer
by: Lee, Ha Yeon, et al.
Published: (2016)

Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer
by: Kim, Seung Tae, et al.
Published: (2016)